Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.39 |
| ▸ | NPY1R | P25929 | 9/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.39 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.37 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22139606 | 1.00 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL21532917 | 0.89 | CACNA1B (0.43) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL21532937 | 0.88 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL20997126 | 0.88 | NPY4R (0.37) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL20997215 | 0.86 | KISS1R (0.36) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL21152809 | 0.84 | C3AR1 (0.35) | FOLH1 | |
| SCHEMBL22068521 | 0.84 | FURIN (0.32) | — | |
| SCHEMBL18594644 | 0.84 | FURIN (0.32) | — | |
| SCHEMBL21013102 | 0.84 | FURIN (0.32) | — | |
| SCHEMBL22068109 | 0.83 | FURIN (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2019-11-05 | — | — | US | disclosed |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | RNGTT, RNASE1, RNMT | NPY4R 3873/4885NPY1R 2894/4885NPY5R 2983/4885 |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | NPY4R 3873/4885NPY1R 2894/4885NPY5R 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.